Abstract
For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan-genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross-resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN.
Keywords:
asunaprevir; daclatasvir; faldaprevir; pegylated interferon; ribavirin; simeprevir; sofosbuvir.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Aminoisobutyric Acids
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Carbamates
-
Clinical Trials as Topic
-
Disease Eradication / methods
-
Disease Eradication / trends*
-
Drug Discovery / methods*
-
Drug Therapy, Combination / methods*
-
Drug Therapy, Combination / trends
-
Hepacivirus / drug effects*
-
Hepacivirus / genetics
-
Hepatitis C / drug therapy*
-
Heterocyclic Compounds, 3-Ring
-
Humans
-
Imidazoles
-
Interferon-alpha
-
Isoquinolines
-
Leucine / analogs & derivatives
-
Oligopeptides
-
Polyethylene Glycols
-
Proline / analogs & derivatives
-
Protease Inhibitors / pharmacology
-
Pyrrolidines
-
Quinolines
-
Recombinant Proteins
-
Ribavirin
-
Simeprevir
-
Sofosbuvir
-
Sulfonamides
-
Thiazoles
-
Uridine Monophosphate / analogs & derivatives
-
Valine / analogs & derivatives
-
Viral Nonstructural Proteins / antagonists & inhibitors
-
Virus Replication / drug effects
-
Virus Replication / physiology*
Substances
-
Aminoisobutyric Acids
-
Antiviral Agents
-
Carbamates
-
Heterocyclic Compounds, 3-Ring
-
Imidazoles
-
Interferon-alpha
-
Isoquinolines
-
Oligopeptides
-
Protease Inhibitors
-
Pyrrolidines
-
Quinolines
-
Recombinant Proteins
-
Sulfonamides
-
Thiazoles
-
Viral Nonstructural Proteins
-
Polyethylene Glycols
-
Ribavirin
-
faldaprevir
-
Proline
-
Simeprevir
-
Uridine Monophosphate
-
NS-5 protein, hepatitis C virus
-
Leucine
-
Valine
-
daclatasvir
-
peginterferon alfa-2a
-
asunaprevir
-
Sofosbuvir